ARWR (Arrowhead Pharmaceuticals) Cyclically Adjusted FCF per Share: $-0.85 (As of Mar. 2026)


ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $86.55
GF Value $51.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share?

Arrowhead Pharmaceuticals ARWR 49 Cyclically Adjusted FCF per Share is $-0.85 as of Mar. 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $51.45 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.575. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.85 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -19.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -13.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Arrowhead Pharmaceuticals was 35.20% per year. The lowest was -32.00% per year. And the median was 18.85% per year.

As of today (2026-07-07), Arrowhead Pharmaceuticals's current stock price is $86.55. Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.85. Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Arrowhead Pharmaceuticals  (NAS:ARWR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 -0.57 -0.79 -1.22 -0.98

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 -1.01 -0.98 -0.92 -0.85

ARWR vs CYTK, TECH, KRYS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.575/330.2130*330.2130
=0.575

Current CPI (Mar. 2026) = 330.2130.

Arrowhead Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.317 241.018 -0.434
201609 -0.199 241.428 -0.272
201612 0.066 241.432 0.090
201703 -0.210 243.801 -0.284
201706 -0.155 244.955 -0.209
201709 -0.124 246.819 -0.166
201712 -0.198 246.524 -0.265
201803 -0.188 249.554 -0.249
201806 -0.167 251.989 -0.219
201809 -0.038 252.439 -0.050
201812 1.753 251.233 2.304
201903 -0.202 254.202 -0.262
201906 0.074 256.143 0.095
201909 0.059 256.759 0.076
201912 -0.287 256.974 -0.369
202003 -0.307 258.115 -0.393
202006 -0.349 257.797 -0.447
202009 -0.128 260.280 -0.162
202012 -0.420 260.474 -0.532
202103 2.471 264.877 3.081
202106 -0.322 271.696 -0.391
202109 -0.309 274.310 -0.372
202112 -0.642 278.802 -0.760
202203 0.537 287.504 0.617
202206 -0.741 296.311 -0.826
202209 -0.958 296.808 -1.066
202212 -1.079 296.797 -1.200
202303 -0.545 301.836 -0.596
202306 -0.630 305.109 -0.682
202309 -0.838 307.789 -0.899
202312 -1.736 306.746 -1.869
202403 -1.026 312.332 -1.085
202406 -1.046 314.175 -1.099
202409 -1.299 315.301 -1.360
202412 -1.232 315.605 -1.289
202503 3.381 319.799 3.491
202506 -1.130 322.561 -1.157
202509 0.094 324.800 0.096
202512 0.081 324.054 0.083
202603 0.575 330.213 0.575

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.85 mean?
Arrowhead Pharmaceuticals (ARWR) has a Cyclically Adjusted FCF per Share of $-0.85 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Arrowhead Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-0.85. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Cyclically Adjusted FCF per Share of $-0.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $51.45, compared to a current price of $86.55 — trading 68.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.85. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Cyclically Adjusted FCF per Share is $-0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $86.55 is trading 68.2% above its estimated GF Value™ of $51.45. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Cyclically Adjusted FCF per Share: $-0.85
  • GF Value™: $51.45 vs. price of $86.55 (68.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$86.55
Price
$51.45
GF Value